Inflammatory Bowel Diseases Clinical Primer and Care Pathway Tool Kit

• Release Date: March 9, 2020
• Expiration Date: September 30, 2021
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

Bincy P. Abraham, MD Fondren Distinguished Professor in Inflammatory Bowel Disease, Department of Medicine Associate Professor of Clinical Medicine, Academic Institute Associate Clinical Member, Research Institute Program Director, Gastroenterology Fellowship Program, Lynda K. and David M. Underwood Center for Digestive Disorders Houston Methodist Weill Cornell Medical College          Click here for biography Jeffrey Dunn, PharmD, MBA Vice President, Clinical Strategy and Program and Industry Relations Magellan Rx Management Click here for biography

Target Audience

• Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
• Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

Statement of Need/Program Overview 

The impact of the advent of targeted biologics has not been more evident in any therapeutic category than anti-inflammatory drugs. However, the historically high cost of these agents has impelled increased management on the part of health plan stakeholders.  In light of current trends toward stricter utilization management, increased member cost-share, and other initiatives that may create a barrier to patient access, managed care professionals and affiliated network providers require education on the economic burden and health care resource utilization of IBD. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in provider practice, payer stakeholders also require an influx of valuable information to effectively address the evolving paradigm of disease management.

Educational Objectives 
At the conclusion of this activity, participants should be able to demonstrate improved ability to: 

1. Characterize the clinical and economic burden of IBD in terms of health care resource utilization, indirect costs, and member quality of life
2. Outline the role of various imaging studies and laboratory tests/assays in the diagnosis of IBD
3. Demonstrate how appropriate access to IBD treatment options can improve clinical and economic outcomes for payers
4. Review clinical trials and the practice guidelines utilized by academic centers for therapeutic selection in IBD
5. Integrate available IBD care pathways from professional organizations into plan infrastructure
6. Employ decision-support tools that assist payers in making fully informed choices about investing resources and designing member benefits for a proactive and personalized treatment approach among patients with IBD

ACCREDITATION

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.00 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-20-1071-H01-P)

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose.
The Crohn’s & Colitis Foundation and Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.